Flagship Pioneering is gearing up to launch a new company that seems to be developing precisely targeted treatments for neurodegenerative conditions, including Parkinson’s.
The new startup, dubbed Vesalius Therapeutics, will be led by Chris Austin, a high-profile recent Flagship recruit who was the founding director of the NIH’s National Center for Advancing Translational Sciences and a senior adviser to the National Human Genome Research Institute. Neurodegenerative conditions are one of his scientific areas of expertise.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
